Skip to main content

Table 1 Clinical and pathological information for 27 adenocarcinomas in the study

From: Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers

Tissueid Age Sex Stage Cell* Diff# Grade+ Status TTLF
Lu1031 57 Female IA AD Well II 0 8.59
Lu1050 58 Male IB AD Well II 0 7.54
Lu1068 57 Female IB AD Mod III 1 3.28
Lu106 63 Male IB AD Well II 0 11.96
Lu113 89 Female IA AD Well II 1 5.68
Lu1182 61 Female IA BAC Well II 0 8.24
Lu1321 68 Female IB AD Well II 0 6.75
Lu1377 64 Female IA AD Well II 0 0.36
Lu1405 54 Female IB AD Mod III 0 8.03
Lu1450 74 Female IB AD Well II 0 8.08
Lu1479 64 Female IA AD Well II 0 8.08
Lu1518 55 Female IB AD Mod III 0 8.01
Lu1606 88 Female IA AD Well II 0 6.75
Lu1659 71 Female IA AD Well II 1 4.09
Lu1682 74 Female IA AD Well II 1 3.60
Lu1790 73 Female IB AD Well II 0 6.20
Lu1821 32 Male IB AD Mod III 0 6.47
Lu1848 46 Female IB AD Well II 0 5.29
Lu1942 70 Male IB AD Mod III 1 1.38
Lu1943 82 Female IB AD Well II 1 5.99
Lu2029 58 Female IB AD Well II 0 6.46
Lu2040 79 Female IB AD Mod III 0 0.78
Lu2368 58 Female IB AD Mod III 1 2.98
Lu2499 74 Female IB BAC Well I 0 5.03
Lu2502 77 Female IA BAC Well II 0 5.13
Lu346 67 Female IA AD Well II 0 5.08
Lu587 72 Female IB BAC Well I 0 5.85
  1. *Tumor cell subtype. AD-adenocarcinoma, BAC-bronchioalveolar carcinoma (adenocarcinoma in situ according to 2011I ASLC/ATS/ERS classification). +Grade – Mayo 4 level grade of differentiation. #Diff – summarized tumor degree of differentiation from grade. I-II well, III- moderate, IV – Poorly/undifferentiated. TTLF – time to last follow up in years; status – 1 death, 0 alive.